Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs’ broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.
External link for Aura Biosciences
80 Guest St
Boston, Massachusetts 02135, US
Aura Biosciences reposted this
Don't miss it! Join Aura Biosciences (#AURA) for a virtual ocular oncology investor event TODAY at 8am ET featuring Dr. Ivana Kim, MD (Mass Eye and Ear) and Dr. Prithvi Mruthyunjaya, MD, MHS (Stanford University Byers Eye Institute) to discuss the Phase 2 end of study data evaluating suprachoroidal administration of bel-sar for the first-line treatment of patients with small choroidal melanoma and indeterminate lesions. Register here: https://bit.ly/3XoQbQi
This morning, Aura reported positive Phase 2 end of study results evaluating bel-sar as a first-line treatment option for early-stage choroidal melanoma. Read the full release here: bit.ly/3TmwKoL
Aura Biosciences reposted this
Join Aura Biosciences (#AURA) for a virtual ocular oncology investor event on Sep. 12 at 8am ET featuring Dr. Ivana Kim, MD (Mass Eye and Ear) and Dr. Prithvi Mruthyunjaya, MD, MHS (Stanford University Byers Eye Institute) to discuss the Phase 2 end of study data evaluating suprachoroidal administration of bel-sar for the first-line treatment of patients with small choroidal melanoma and indeterminate lesions. Register here: https://bit.ly/3XoQbQi
Aura announced the Phase 2 end of study data of bel-sar will be presented at The Retina Society Annual Meeting. In addition, Aura will host a virtual ocular oncology investor event on September 12, 2024, at 8:00 am ET. To register for the Aura virtual event, click here: https://bit.ly/3X1xnoH
Aura’s second quarter 2024 financial results and corporate update are now available. Read the full press release here: https://bit.ly/3X63Co9
Happy National Intern Day! Thanks to our summer interns, Denise Nguyen, DJ Johnston, and Sol Feder, for all of their hard work this summer!
Aura Biosciences CMO and President of R&D J. Jill Hopkins, MD recently spoke with Healio about our ongoing Phase 3 trial in #ChoroidalMelanoma. Check out the full video here: https://lnkd.in/e7z5AwdX
A phase 3 program will investigate bel-sar delivered through a suprachoroidal injection and activated with a laser in patients with #choroidalmelanoma. J. Jill Hopkins, MD, of Aura Biosciences discusses the program 👇 #OcularSurgeryNews #CTSRetina CTS Retina https://lnkd.in/e7z5AwdX
Wishing everyone a safe and relaxing Fourth of July holiday! #IndependenceDay
Tomorrow, Aura’s offices will be closed in recognition of #Juneteenth. This is an important day that Aura is proud to celebrate as we continue to strive toward #equity and #equality nationwide.
During #CancerSurvivorsMonth, we’re sharing inspiration from those who have battled the disease. Aura’s very own Tish Webb, Executive Director, Clinical Portfolio Lead, shares her inspiring story about surviving her breast cancer diagnosis. #oncology
Letzte Runde
Eigenkapital nach dem IPOUS$ 99.0M